Health Care Equipment

Lepu Medical

Lepu Medical released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 1.544 B (forecast CNY 1.673 B), actual EPS CNY -0.0108 (forecast CNY 0.0694)

Lepu Medical released FY2025 earnings on April 23 After-Market (BJT), actual revenue CNY 6.483 B (forecast CNY 6.635 B), actual EPS CNY 0.5219 (forecast CNY 0.5912)

Lepu Medical released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 1.672 B (forecast CNY 1.992 B), actual EPS CNY 0.1339 (forecast CNY 0.213)

Lepu Medical to Release FY2026 Q1 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 1.992 B, EPS CNY 0.213

Lepu Medical to release FY2025 earnings on April 23 After-Market (BJT), forecast revenue CNY 6.635 B, EPS CNY 0.5912

Lepu Medical released FY2025 9 Months earnings on October 24 After-Market (BJT), actual revenue CNY 4.939 B, actual EPS CNY 0.5326

Lepu Medical released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 1.569 B (forecast CNY 1.937 B), actual EPS CNY 0.1579 (forecast CNY 0.1498)

Lepu Medical to release FY2025 Q3 earnings on October 25 After-Market BJT, forecast revenue CNY 1.937 B, EPS CNY 0.1498

National Procurement of Sixth Batch of High-Value Medical Consumables Launched for Drug-Coated Balloons and Urological Interventional Materials

Leple Medical Reduces HeartSure Medical H Shares via Block Trades

Lepu Medical released FY2025 Q2 earnings on August 22 After-Market (BJT), actual revenue CNY 1.633 B (forecast CNY 1.609 B), actual EPS CNY 0.1694 (forecast CNY 0.123)

Lepu Medical released FY2025 Semi-Annual earnings on August 22 After-Market (BJT), actual revenue CNY 3.369 B, actual EPS CNY 0.3748

Lepu Medical FY2025 Semi-Annual Earnings Release on August 23, 2025 (BJT)

Le 普 Medical Receives Approval for Hyaluronic Acid Sodium Solution

Leple (Beijing) Medical Device Submitted New Trademark Registration Application

Lepu Medical Co-contributes to Huaxia Zhiyuan Venture Fund

HuAn Securities Maintains Buy Rating for LeapMed

Lepu Medical's Juvederm Needle Receives NMPA Registration Approval

Lepu Medical's Juvederm Alternative Approved by NMPA

Huansan Securities Gives 'Buy' Rating to Lepu Medical

300003

Lepu Medical's subsidiary, Lepu Medical Electronics, has obtained registration approval from the National Medical Products Administration (NMPA) for its self-developed rechargeable implantable deep brain stimulation system product. This technology regulates neural electrical activity in the brain through implanted electrodes, providing new treatment options for Parkinson's disease patients and marking an important advancement for the company in the field of neuromodulation

Zhitong

Lepu Medical: Rechargeable implantable deep brain stimulation system product has received registration approval

Lepu Medical stated at the earnings briefing that the implantable deep brain stimulation device is expected to be approved for market launch soon, with revenue contributions anticipated next year. The implantable cardiac contractility modulator is set to be filed in the first and second quarters of next year. The neuroregulation business segment will provide new logic for the company's performance growth. In the context of centralized procurement, the company is committed to developing implantable medical devices with higher technological barriers and better market competition patterns in the field of major clinical demand disease diagnosis and treatment, thereby reducing the impact of centralized procurement policies on the company's business

Lepu Medical: The implanted deep brain stimulation device is expected to be approved for market launch soon and is likely to contribute to revenue next year

According to the Zhitong Finance APP, Lepu Medical released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 4.939 billion yuan, a year-on-year increase of 3.20%. The net profit attributable to shareholders of the listed company was 982 million yuan, a year-on-year increase of 22.35%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 941 million yuan, a year-on-year increase of 28.18%. The basic earnings per share were 0.5327 yuan

Lepu Medical released its performance for the first three quarters, with a net profit attributable to the parent company of 982 million yuan, an increase of 22.35%

Lepu Medical announced that its revenue for the third quarter was 1.569 billion yuan, a year-on-year increase of 11.97%; net profit was 291 million yuan, a year-on-year increase of 176.18%. Revenue for the first three quarters was 4.939 billion yuan, a year-on-year increase of 3.20%; net profit was 982 million yuan, a year-on-year increase of 22.35%

Lepu Medical: Third-quarter net profit of 291 million yuan, a year-on-year increase of 176.18%

Lepu Medical signed a strategic cooperation agreement with Hanhai Information, authorizing Hanhai Information to promote and operate the medical beauty sector brands. Hanhai Information will provide online and offline resources, deeply collaborating on the full-chain marketing of the Yueyayan and Flora products, including strategy formulation, sales execution, and after-sales operations, to jointly protect brand interests. Hanhai Information is the core company of Meituan in Shanghai and holds complete platform operating rights

Lepu Medical signs a strategic cooperation agreement with HanHai Information

09926

002139

Three Asian growth companies with significant insider ownership are highlighted for their expected revenue growth: Akeso (SEHK:9926) forecasts 34.4% annual growth, driven by its innovative cancer therapies; Shenzhen Topband (SZSE:002139) anticipates 15.6% growth, supported by global expansion; and Lepu Medical Technology (SZSE:300003) expects 14.1% growth, despite recent profit margin declines. These companies reflect strong confidence from insiders and are positioned to outperform their respective markets, although some may be priced higher than justified based on financials.

Simplywall

AKESO

Topband

3 Asian Growth Companies With Insider Ownership Expecting Up To 34% Revenue Growth

According to the Zhitong Finance APP, Lepu Medical announced that its holding subsidiary Shanghai Minwei Biotechnology Co., Ltd. (referred to as "Minwei Biotechnology") has independently developed the innovative drug MWN105 injection, which is currently conducting a Phase II clinical trial for the treatment of overweight or obesity, and has recently successfully completed the administration for the first subject

Lepu Medical: The first subject has been dosed in the Phase II clinical trial of MWN105 injection

02291

SCIENTECH announced that its controlling shareholder Lepu Medical reduced its holdings by 11.14 million H shares through block trading at HKD 22.79 per share, accounting for approximately 3.21% of the issued shares. After the reduction, Lepu Medical still holds 268.86 million shares, accounting for approximately 77.54% of the total share capital. Lepu Medical stated that it is confident in the company's business operations, and the reduction aims to enhance stock liquidity

SCIENTECH

SCIENTECH received a reduction of 11.14 million H shares from its controlling shareholder Lepu Medical

Lepu Medical(300003.SZ)